Literature DB >> 25516468

Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes.

I Gómez-Touriño1, R Simón-Vázquez, J Alonso-Lorenzo, S Arif, C Calviño-Sampedro, Á González-Fernández, E Pena-González, J Rodríguez, J Viñuela-Roldán, J Verdaguer, O J Cordero, M Peakman, R Varela-Calvino.   

Abstract

Type 1 diabetes results from destruction of insulin-producing beta cells in pancreatic islets and is characterized by islet cell autoimmunity. Autoreactivity against non-beta cell-specific antigens has also been reported, including targeting of the calcium-binding protein S100β. In preclinical models, reactivity of this type is a key component of the early development of insulitis. To examine the nature of this response in type 1 diabetes, we identified naturally processed and presented peptide epitopes derived from S100β, determined their affinity for the human leucocyte antigen (HLA)-DRB1*04:01 molecule and studied T cell responses in patients, together with healthy donors. We found that S100β reactivity, characterized by interferon (IFN)-γ secretion, is a characteristic of type 1 diabetes of varying duration. Our results confirm S100β as a target of the cellular autoimmune response in type 1 diabetes with the identification of new peptide epitopes targeted during the development of the disease, and support the preclinical findings that autoreactivity against non-beta cell-specific autoantigens may have a role in type 1 diabetes pathogenesis.
© 2014 British Society for Immunology.

Entities:  

Keywords:  S100β; Th1; autoimmunity; peptide epitopes; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 25516468      PMCID: PMC4408155          DOI: 10.1111/cei.12572

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  PCR-sequence-specific primer typing of HLA class I and class II alleles.

Authors:  Mike Bunce
Journal:  Methods Mol Biol       Date:  2003

2.  Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.

Authors:  Sefina Arif; Timothy I Tree; Thomas P Astill; Jennifer M Tremble; Amanda J Bishop; Colin M Dayan; Bart O Roep; Mark Peakman
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

4.  Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation.

Authors:  Elsa Laughlin; George Burke; Alberto Pugliese; Ben Falk; Gerald Nepom
Journal:  Clin Immunol       Date:  2008-05-02       Impact factor: 3.969

5.  Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives.

Authors:  Nathan E Standifer; Qin Ouyang; Constadina Panagiotopoulos; C Bruce Verchere; Rusung Tan; Carla J Greenbaum; Catherine Pihoker; Gerald T Nepom
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

Review 6.  S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature).

Authors:  Ingo Marenholz; Claus W Heizmann; Günter Fritz
Journal:  Biochem Biophys Res Commun       Date:  2004-10-01       Impact factor: 3.575

7.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.

Authors:  D L Kaufman; M Clare-Salzler; J Tian; T Forsthuber; G S Ting; P Robinson; M A Atkinson; E E Sercarz; A J Tobin; P V Lehmann
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

8.  Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects.

Authors:  Junbao Yang; Nancy A Danke; DeAnna Berger; Sandra Reichstetter; Helena Reijonen; Carla Greenbaum; Catherine Pihoker; Eddie A James; William W Kwok
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

9.  Targeting of pancreatic glia in type 1 diabetes.

Authors:  Hubert Tsui; Yin Chan; Lan Tang; Shawn Winer; Roy K Cheung; Geoffrey Paltser; Thirumahal Selvanantham; Alisha R Elford; James R Ellis; Dorothy J Becker; Pamela S Ohashi; Hans-Michael Dosch
Journal:  Diabetes       Date:  2008-01-15       Impact factor: 9.461

10.  Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death.

Authors:  Sefina Arif; Fabrice Moore; Katherine Marks; Thomas Bouckenooghe; Colin M Dayan; Raquel Planas; Marta Vives-Pi; Jake Powrie; Timothy Tree; Piero Marchetti; Guo Cai Huang; Esteban N Gurzov; Ricardo Pujol-Borrell; Decio L Eizirik; Mark Peakman
Journal:  Diabetes       Date:  2011-06-09       Impact factor: 9.461

View more
  5 in total

Review 1.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 2.  T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.

Authors:  Adam L Burrack; Tijana Martinov; Brian T Fife
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-05       Impact factor: 5.555

3.  Naturally presented HLA class I-restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes.

Authors:  Cristina Calviño-Sampedro; Iria Gomez-Tourino; Oscar J Cordero; Pedro A Reche; Marta Gómez-Perosanz; Jose Luis Sánchez-Trincado; Miguel Ángel Rodríguez; Aurelio M Sueiro; Juan E Viñuela; Rubén Varela Calviño
Journal:  FASEB J       Date:  2019-02-28       Impact factor: 5.191

4.  Comparison of HLA ligand elution data and binding predictions reveals varying prediction performance for the multiple motifs recognized by HLA-DQ2.5.

Authors:  Zeynep Koşaloğlu-Yalçın; John Sidney; William Chronister; Bjoern Peters; Alessandro Sette
Journal:  Immunology       Date:  2020-11-03       Impact factor: 7.397

5.  Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial (PRIDe): a phase IV multicenter, randomized, placebo-controlled, double-blind clinical trial of ketamine versus haloperidol for prevention of postoperative delirium.

Authors:  Harriet Riegger; Alexa Hollinger; Burkhardt Seifert; Katharina Toft; Andrea Blum; Tatjana Zehnder; Martin Siegemund
Journal:  Trials       Date:  2018-02-26       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.